These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 5749260)

  • 21. [The presence of plasminogen activator in kidney perfusate].
    Zuch A; Januszko T; Buluk K; Bielecki T
    Przegl Lek; 1973; 30(6):504-9. PubMed ID: 4732444
    [No Abstract]   [Full Text] [Related]  

  • 22. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Blood coagulation mechanism from the viewpoint of molecular biochemistry: Mechanism of fibrinolysis].
    Matsuda T
    Rinsho Byori; 1985 Sep; 33(9):982-8. PubMed ID: 2416968
    [No Abstract]   [Full Text] [Related]  

  • 24. Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review).
    Chorostowska-Wynimko J; Skrzypczak-Jankun E; Jankun J
    Int J Mol Med; 2004 Jun; 13(6):759-66. PubMed ID: 15138609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding of 99mTc plasminogen on fibrin.
    Juhan-Vague I; Calas MF; Roux F; Juhan C; Durand-Dessemon F; de Laforte C; Serradimigni A
    Thromb Haemost; 1981 Apr; 45(2):154-7. PubMed ID: 6789493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of gamma interferon in human subjects decreases plasminogen activation and fibrinolysis without influencing C1 inhibitor.
    Gluszko P; Undas A; Amenta S; Szczeklik A; Schmaier AH
    J Lab Clin Med; 1994 Feb; 123(2):232-40. PubMed ID: 8301199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Development of research into the physiology and pathophysiology of the fibrinolysis system].
    Andreenko GV
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1985; (10):5-19. PubMed ID: 2933082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Kinetic characteristics of the activation of various structural forms of plasminogen by tissue activator in the presence of fibrin].
    Taran LD; Makagonenko EM; Nazarenko NA; Kudinov SA
    Biokhimiia; 1986 Aug; 51(8):1256-61. PubMed ID: 3094590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early local and systemic fibrinolytic response to high energy missile trauma.
    Almskog B; Risberg B; Teger-Nilsson AC; Seeman T
    Acta Chir Scand Suppl; 1982; 508():327-36. PubMed ID: 6177148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2.
    Perides G; Noring R; Klempner MS
    Biochem Biophys Res Commun; 1996 Feb; 219(3):690-5. PubMed ID: 8645243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
    Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
    Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrinolytic agents: mechanisms of activity and pharmacology.
    Lijnen HR; Collen D
    Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Inhibition of esterase by L-lysine, the activator and fibrinolytic activity of the plasmin-streptokinase activator complex].
    Aĭsina RB; Gaĭsarian ES; Snitko IaE; Varfolomeev SD
    Bioorg Khim; 1994 Feb; 20(2):182-9. PubMed ID: 8155080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
    Robbie LA; Booth NA; Croll AM; Bennett B
    Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Enzymatic fibrinolytic agents].
    Jamet M; Granthil C; Levy G
    Ann Anesthesiol Fr; 1978; 19(8):693-6. PubMed ID: 31112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen activator in the cytoplasmic granules from different organs of mammals: studies on intracellular localization, releasing, and molecular size of two kinds of the activators.
    Sugiyama Y
    Kobe J Med Sci; 1965 Dec; 11(4):151-67. PubMed ID: 5882822
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of the histochemical method for studying the fibrinolytic activities of tissue sections.
    Rejniak L; Prokopowicz J; Niewiarowski S; Worowski K
    Folia Histochem Cytochem (Krakow); 1966; 4(3):325-31. PubMed ID: 5919083
    [No Abstract]   [Full Text] [Related]  

  • 39. [Proceedings: 69. On the releasing mechanism of plasminogen-activator from the isolated hind leg of dog (author's transl)].
    Kitaguchi H
    Nihon Seirigaku Zasshi; 1973; 35(8):410. PubMed ID: 4799270
    [No Abstract]   [Full Text] [Related]  

  • 40. Release of plasminogen activator from viable leukocytes of man, baboon, dog and rabbit.
    Wünschmann-Henderson B; Horwitz DL; Astrup T
    Proc Soc Exp Biol Med; 1972 Nov; 141(2):634-8. PubMed ID: 4636533
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.